Robot-assisted partial nephrectomy in morbidly obese patients: a VCQI database study.

Journal: Journal of robotic surgery
PMID:

Abstract

To compare perioperative outcomes following robot-assisted partial nephrectomy (RAPN) in patients with morbid obesity (body mass index (BMI > 40 kg/m)) and non-obese patients. Using the Vattikuti Collective quality initiative (VCQI) database for RAPN, data for morbidly obese and non-obese patients was obtained. Propensity scores were calculated for two treatment groups (morbidly obese vs. non-obese) for the following variables i.e. age, sex, tumor size, RNS, surgical access (retroperitoneal/transperitoneal) and estimated glomerular filtration rate (eGFR) to ensure comparability. The primary outcome for the study was comparison of trifecta between the two groups. In this study, 158 morbidly obese patients were matched with 158 non-obese patients undergoing RAPN. Two groups matched well for age, sex, tumor size, eGFR and RNS. There was no difference between two groups for ischemia time, blood loss, blood transfusion, conversion to radical nephrectomy, length of stay, intraoperative and postoperative complications. Operative time was longer in morbidly obese patients (median 210 min vs. 120 min, p = 0.000). On pathological analysis, malignant tumors were more likely in the morbidly obese group (83.1% vs.73.4%, p = 0.018). Trifecta outcomes were comparable between the two groups (60.1% vs. 63.3%, p = 0.563). The Median duration of follow-up was 12 months (1-96 months). The morbidly obese group had significantly higher day one creatinine (1.25 ± 0.7 vs. 1.07 ± 0.37, p = 0.001) and significantly lower day one eGFR (62.1 ± 19 vs. 69.2 ± 21, p = 0.018). However, there was no difference between the two groups for the last follow-up creatinine and eGFR. RAPN in morbidly obese patients is associated with equivalent perioperative outcomes compared to non-obese patients.

Authors

  • Gopal Sharma
    Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Gurpremjit Singh
    Department of Urologic Oncology, Medanta The Medicity, Gurgaon, India.
  • Puneet Ahluwalia
    Max Institute of Cancer Care, Max Superspeciality Hospital, New Delhi, India.
  • Prokar Dasgupta
  • Benjamin J Challacombe
    Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Mahendra Bhandari
  • Rajesh Ahlawat
  • Sudhir Rawal
    Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
  • Nicolò M Buffi
    Humanitas Research Hospital, Milan, Italy.
  • Sivaraman Ananth
    Chennai Urology and Robotics Institute, Apollo Hospitals, Greams Lane, Chennai, India.
  • James R Porter
    Swedish Medical Centre, Seattle, WA, USA.
  • Craig Rogers
    Department of Urology, Henry Ford Health System, Detroit, MI, USA.
  • Alexandre Mottrie
    ORSI Academy Melle Belgium.
  • Ronney Abaza
    OhioHealth Robotic Urologic and Cancer Surgery, Dublin Methodist Hospital, Dublin, Ohio.
  • Khoon Ho Rha
    Yonsei University Health System, Seoul, South Korea.
  • Daniel Moon
    Peter MacCallum Hospital, University of Melbourne, Royal Melbourne Clinical School, Melbourne, Australia.
  • Thyavihally B Yuvaraja
    Kokilaben Dhirubhai Ambani Hospital, Mumbai, India.
  • Dipen J Parekh
    Miller School of Medicine, University of Miami, Miami, FL, USA. Electronic address: parekhd@miami.edu.
  • Umberto Capitanio
    Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Milan, Italy.
  • Kris K Maes
    Centre for Robotic and Minimally Invasive Surgery, Hospital Da Luz, Luz Sáude, Portugal.
  • Francesco Porpiglia
    Division of Urology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
  • Levent Türkeri
    Acibadem University School of Medicine, Istanbul, Turkey.
  • Gagan Gautam
    Division of Urologic Oncology, Max Institute of Cancer Care, Saket, New Delhi, India.